Expert Opinion On Drug Discovery

雜志介紹

Expert Opinion On Drug Discovery雜志介紹

《Expert Opinion On Drug Discovery》是一本以English為主的未開放獲取國際優秀期刊，中文名稱關于藥物發現的專家意見，本刊主要出版、報道醫學-PHARMACOLOGY & PHARMACY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為6，最新CiteScore 指數為10.2。

本刊近期中國學者發表的論文主要有：

• The discovery and design of novel HIV-1 capsid modulators and future perspectives

  Author: Ding, Dang; Xu, Shujing; Zhang, Xujie; Jiang, Xiangyi; Cocklin, Simon; Dick, Alexej; Zhan, Peng; Liu, Xinyong

• Latest developments in engineered skeletal muscle tissues for drug discovery and development

  Author: Ostrovidov, Serge; Ramalingam, Murugan; Bae, Hojae; Orive, Gorka; Fujie, Toshinori; Shi, Xuetao; Kaji, Hirokazu

• Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets

  Author: Yang, Tao; Wang, Si Chun; Ye, Linyan; Maimaitiyiming, Yasen; Naranmandura, Hua

• Computational approaches for the design of modulators targeting protein-protein interactions

  Author: Rehman, Ashfaq Ur; Khurshid, Beenish; Ali, Yasir; Rasheed, Salman; Wadood, Abdul; Ng, Ho-Leung; Chen, Hai-Feng; Wei, Zhiqiang; Luo, Ray; Zhang, Jian

英文介紹

Expert Opinion On Drug Discovery雜志英文介紹

Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.

The Editors welcome:

Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology

Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug

The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.